Arbeitsgruppe Hepatobiliäre Tumoren - Studien
| HCC - frühes Stadium |
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-HEP-0417/ass: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC) (IMMULAB) | ||||
| --- in Rekrutierung --- | ||||
| HCC - intermediäres Stadium |
| AIO-assoziierte Studie | Für weitere Zentren offen |
|
zur Studie | |
| AIO-HEP-0220/ass: Transarterial chemoembolization (TACE) with Irinotecan and Mitomycin C versus TACE with Doxorubicin in patients with Hepatocellular carcinoma not amenable to curative treatment - IRITACE- a randomized multicenter phase 2 trial. A trial of the German Alliance for Liver Cancer (GALC). - IRITACE |
||||
| --- in Rekrutierung --- | ||||
| AIO-Studie | weitere Zentren auf Anfrage |
www.clinicaltrials.gov | zur Studie | |
| AIO-HEP-0418: A randomized, 2-arm non-comparative phase II study on the effects of atezolizumab and Roche bevacizumab (atezo/bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and atezo/bev on 24-Months survival rate in the treatment of BCLC B hepatocellular carcinoma patients. (DEMAND) |
||||
| --- in Vorbereitung --- | ||||
| AIO-assoziierte Studie | Für weitere Zentren offen |
|
zur Studie | |
| AIO-HEP-0319/ass: A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design - IMMUWIN |
||||
| --- in Rekrutierung --- | ||||
| HCC - fortgeschrittenes Stadium, 1st-line |
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-HEP-0218/ass: An open-label, single-arm phase II study of immunotherapy with nivolumab in combination with lenvatinib for advanced stage hepatocellular carcinoma (HCC) [IMMUNIB] | ||||
| --- in Rekrutierung --- | ||||
| HCC - fortgeschrittenes Stadium, 2nd-line |
| AIO-assoziierte Studie | zur Studie | |||
| AIO-HEP-0121/ass: A phase-II open-label study of pembrolizumab and lenvatinib in patients with advanced stage hepatocellular carcinoma who are refractory to atezolizumab and bevacizumab/ IO-based therapy (SOLARIS) |
||||
| --- in Vorbereitung--- | ||||
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-HEP-0320/ass: A phase II study evaluating
reduced starting dose and dose escalation of Cabozantinib as second-line
therapy for advanced HCC in patients with compensated liver cirrhosis
(CaboRISE) |
||||
| --- in Rekrutierung--- | ||||
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-
HEP-0419/ass: A Phase II,
non-randomized, single arm, translational study of CAbozantinib for Patients
with HepatocellUlaR CarcinOma (HCC) Refractory to LenvAtinib Treatment (AURORA) |
||||
| --- in Rekrutierung--- | ||||
| AIO-assoziierte Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-HEP-0318/ass: A phase I/II multicenter, open-label Study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in Patients with Hepatocellular Carcinoma and WNT signaling Alterations | ||||
| --- in Rekrutierung--- | ||||
| CCA - adjuvant |
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-HEP-0112: Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1). A randomized, multidisciplinary, multinational AIO/DGAV/DGVS phase III trial | ||||
| ---in Rekrutierung--- | ||||
| CCA - neoadjuvant |
| AIO-assoziierte Studie | Für weitere Zentren offen | www.clinicaltrials.gov | zur Studie | |
| AIO-HEP-0118/ass: Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – A phase III study utilizing the German Registry of Incidental Gallbladder Carcinoma Platform (GR) – The AIO/ CALGP/ ACO- GAIN-Trial - |
||||
| ---in Rekrutierung --- weitere Zentren sind sehr erwünscht! --- | ||||
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-HEP-0120: Neoadjuvante Therapie mit Bintrafusp alfa bei
Patienten mit operablem Krebs der Gallenwege (NEOBIL) |
||||
| --- in Vorbereitung --- | ||||
| Biliäre Tumoren - 1st-line |
| AIO-assoziierte Studie | Für weitere Zentren offen | www.clinicaltrials.gov | zur Studie | |
| AIO-HEP-0119/ass: A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care [IMMUWHY] | ||||
| --- in Rekrutierung --- | ||||
| Biliäre Tumoren - 2nd-line |
| AIO-Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-HEP-0116: A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine or gemcitabine containing therapies (NALIRICC) | ||||
| ---in Rekrutierung--- | ||||
| AIO-Studie | www.drks.de | zur Studie | ||
| AIO-YMO/HEP-0316: 5-Fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (IRIBIL): a randomized open-label phase 2 study (IRIBIL) | ||||
| ---in Rekrutierung--- | ||||
| Register:
Hepatozelluläres Karzinom / Gallengangskarzinom / Gallenblasenkarzinom /
Pankreaskarzinom / Magen- und
Speiseröhrenkarzinom – palliativ, 1st-line |
| AIO-assoziierte Studie | Für weitere Zentren offen | www.clinicaltrials.gov | zur Studie | |
| AIO-HEP/STO-0219/ass: PLATON Pilot-StudyPlatform for Analyzing Targetable Tumor Mutations – PLATON (Pilot-Study) and The PLATON Network (Main-Study) | ||||
| --- in Rekrutierung --- | ||||
| LETZTE AKTUALISIERUNG DIESER SEITE AM: 19.03.2021 |